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Abstract
Purpose Comparative evidence regarding the responsive-
ness of the EQ-5D and SF-6D in arthritis patients is con-
ﬂicting and insufﬁcient across the range of disease severity.
We examined the comparative responsiveness of the EQ-5D
and SF-6D in cohorts of patients with early inﬂammatory
disease through to severe rheumatoid arthritis (RA).
Methods Responsiveness was tested using the effect size
(ES) and standardised response mean (SRM). Correlation
of change in EQ-5D and SF-6D with disease speciﬁc
measures was tested using Pearson correlations and the
Steiger’s Z test. Treatment response and self-reported
change were used as anchors of important change.
Results The EQ-5D was more responsive to deterioration
(ES ratio (EQ-5D/SF-6D): 1.6–3.0) and the SF-6D more
responsive to improvement (ES ratio (SF-6D/EQ-5D):
1.1–1.8) in health. The SF-6D did not respond well to
deterioration in patients with established severe RA (ES
and SRM 0.08). The EQ-5D provided larger absolute
mean change estimates but with greater variance compared
to the SF-6D.
Conclusions The comparative responsiveness of the
EQ-5D and SF-6D differs according to the direction of
change. The level of mean change of the EQ-5D relative to
the SF-6D has implications for cost-effectiveness analysis.
Use of the SF-6D in patients with severe progressive disease
may be inappropriate.
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Background
There is an increasing demand for economic evaluations of
health care which compare the costs and beneﬁts of inter-
ventions in order to identify which provide the greatest
health gain per unit of investment. Assessments based on
quality-adjusted life years (QALYs) gained are recom-
mended for economic evaluation of new interventions [1]
and have been adopted by decision-making organisations
in many countries including the United Kingdom [2],
Canada [3] and the USA [4]. QALYs are the product of the
time spent in a health state multiplied by a utility value,
representing quality of life, for that particular health state.
Utility is the preference for a health state (rated in the
presence of choice) relative to full health (scored 1) and
death (scored 0).
Decision makers such as the National Institute for
Health and Clinical Excellence (NICE) in the United
Kingdom aim to maximise the health of the population.
They, therefore, require preference data from a represen-
tative sample of the public based on ratings of health states
described using standardised validated generic instruments
using a choice-based method [5]. This allows interventions
for a range of different diseases and specialties to be
assessed on a standard scale. Generic instruments devel-
oped for this purpose include the EQ-5D and SF-6D. The
EQ-5D has a number of country-speciﬁc choice-based
preference weights including the United Kingdom and the
USA, whilst the SF-6D to date has only UK preference
weights.
In the United Kingdom, NICE currently suggests that the
most appropriate measure is the EQ-5D but recognises that
the EQ-5D may not be appropriate in all circumstances. The
SF-6D has considerable potential as it can be calculated
from both SF-36 [6] and SF-12 [7], which have been rou-
tinely collected in numerous studies. The choice of prefer-
ence-based measure, however, depends on the validity of
the measure in that setting. The EQ-5D is one the most
extensively validated measures for use in patients with
rheumatoid arthritis (RA) [8]. The SF-6D has been less
extensively studied in this setting, but evidence to date
suggests the measure has potential [8].
One important test of validity is the ability of a measure
to reﬂect the change in patients over time. The EQ-5D and
SF-6D have been shown to be capable of detecting some
degree of change in RA patients [9–12] The responsiveness
of the EQ-5D and SF-6D have been compared head-to-
head in North American populations, but not to date in UK
or European populations. In two studies of North American
populations, the SF-6D appeared more responsive than the
EQ-5D to improvement in patients health [10, 11]. How-
ever, other results have been conﬂicting. In patients with
one of a number of rheumatological conditions (51% RA),
the EQ-5D was more responsive than the SF-6D to
improvement [12]. A recent review of the use of generic
utility measures in RA recommended more head-to-head
comparisons of the measures in longitudinal studies across
the spectrum of RA disease severity [8].
We aimed to compare the responsiveness to change of
the EQ-5D and SF-6D in UK patients from a range of
studies covering early inﬂammatory arthritis through to
severe RA.
Methods
Data were taken from four cohorts of patients:
1. TheSteroidsinVeryEarlyArthritis(STIVEA)random-
ised controlled trial (RCT) of intramuscular steroid
treatment versus placebo in patients with very early
inﬂammatory arthritis (4–11 weeks duration). The trial
follow-up ﬁnished in late 2007 [13]. At the time of this
analysis, the STIVEA trial remained blinded. There-
fore, the patients studied comprised patients receiving
either active or placebo treatment, but the proportion
receiving each allocation is unknown.
2. British Rheumatoid Outcome Study Group (BROSG)
RCT of aggressive versus symptomatic control of
inﬂammation in patients with established ([5 years
duration) stable, symptomatic rheumatoid arthritis
(RA) followed for 3 years. The BROSG trial was
conducted between 1998 and 2001 [14].
3. A subsample from the British Society for Rheumatol-
ogy Biologics Register (BSRBR) of RA patients treated
with anti-TNF therapy and followed for 6 months. The
BSRBR was established in October 2001, and the
methods of this study have been described in detail
previously [15]. As part of the current study, from 1st
August 2006 to 31st December 2007, newly enrolled
patients were also asked to complete the EQ-5D at
baseline and the 6-month assessment.
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1234. A subsample of patients in the control arm of BSRBR,
who also received the EQ-5D at baseline and 6-month
assessment in the same time period as the anti-TNF
treatment cohort. These patients were biologic-naive
with active RA (guideline DAS28 [4.2) currently
treated with Disease Modifying Anti-Rheumatic Drugs
(DMARDs) and were recruited in parallel within the
BSRBR and followed up with identical methodology.
Baseline data for all cohorts included age, sex and dis-
ease duration. All patients completed the EQ-5D [16] and
the SF-36 [17] (used to calculate the SF-6D utility measure
[6]) and the Health Assessment Questionnaire (HAQ), a
measure of functional disability. A patient global assess-
ment, the 28 tender and swollen joint counts and the
erythrocyte sedimentation rate (ESR) were also collected,
which enabled the Disease Activity Score (DAS28) [18]t o
be calculated. In the BSRBR control arm, the composite
DAS28 score was frequently reported in isolation without
separate 28 tender and swollen joint counts and the ESR.
Higher HAQ (range 0–3), DAS28 (range 0–10), tender and
swollen joint counts (range 0–28) and ESR denote more
severe disease (Table 1). Lower EQ-5D and SF-6D scores
denote poorer HRQoL.
Expectations of improvement/deterioration
These four cohorts reﬂect a range of arthritis states/severity
found in routine practice from ﬁrst presentation with
undifferentiated inﬂammatory arthritis through long-stand-
ing established RA to patients with severe, active disease.
The health-related quality of life (HRQoL) of patients with
early disease (STIVEA trial) and active disease patients
BSRBR anti-TNF treatment arm was expected to improve.
Patients from STIVEA may improve in response to steroid
treatment, by natural remission which may be expected to
occur in up to 25% of patients [19, 20], or by adaptation—
improvements in functional disability are often seen in the
early stages of RA [21, 22]. Patients in the BSRBR
receiving treatments which inhibit the action of TNFa were
expected to have dramatically improved outcome [23–25].
Improvement in response to treatment was assessed
according to the European League Against Rheumatism
(EULAR) response criteria deﬁnition based on the DAS28
[26]. Responders were patients achieving a good or mod-
erate EULAR response. Good responders improve by[1.2
units on the DAS28 score and achieve an absolute DAS28
score\3.2 at 6 months. Non-responders improve\0.6 and
have a 6-month DAS28 score [5.1. Moderate responders
fall in between these deﬁnitions.
Patients with long-standing established (BROSG) and
severe disease (BSRBR control) receiving DMARD treat-
ment were expected to experience disease progression
which would be reﬂected by deteriorating HRQoL. Suc-
cessful DMARD treatment is expected to slow disease
progression [27], but patients with long disease duration
are less likely to respond to DMARD treatment [28, 29].
Change in EQ-5D and SF-6D over the ﬁrst year of the
BROSG trial was assessed in relation to the EuroQol
‘feelings thermometer’ visual analogue scale (EQ-VAS).
The EQ-VAS asks the respondent to indicate ‘‘how good or
bad is your health today, in your opinion’’ on a verti-
cal 0–100 scale. Change between baseline and 1-year
follow-up was calculated as a percentage change using
the formula ((EQ-VAS2 - EQ-VAS1)/EQ-VAS1) 9 100.
The percentage change was then deﬁned as small if it was
between 20 and 50% similar to the methods of Marra et al.
[10].
Table 1 Summary of outcome measures used in this study
Type of measure Range of scores Minimum important difference
Worst Best
EQ-5D Preference-based utility measure/HRQoL -0.59 1.00 0.05–0.13 [8]
SF-6D Preference-based utility measure/HRQoL 0.30 1.00 0.03–0.04 [8]
EQ-VAS Global self-rated health assessment 0 100 9–29 for global health VAS scales [48]
HAQ Functional disability 3 0 Generally 0.20–0.25 [48, 49]; -0.09 to 0.21 for
improvement, 0.15–0.48 for deterioration [42, 48]
DAS28 Disease activity 9.1
a 0 0.6 based on EULAR response criteria [26]
28 Tender joint count Physician assessment of tenderness
in 28 joints
28 0 N/k
28 Swollen joint count Physician assessment of swelling
in 28 joints
28 0 N/k
ESR (mm/h) Laboratory test of inﬂammatory
marker/acute phase reactant
b 0 N/k
HRQoL health-related quality of life, ESR erythrocyte sedimentation rate, N/k not known
a Using an ESR value of 100;
b higher values indicate inﬂammation
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improvement or deterioration, and the magnitude of
expected change within these groups was estimated using
‘benchmark’ criteria for effect sizes of small (ES = 0.2),
moderate (ES = 0.5) and large (ES = 0.8) [30].
We expected
1. moderateEQ-5DandSF-6Dimprovements(ES * 0.5)
in STIVEA patients based on the known improvement
in symptoms of patients in early arthritis (for example
improvements in HAQ, pain and SF-36 HRQoL),
steroid treatment which reduces inﬂammation and
may slow the progression of disease, and the possibility
of disease remission [22, 31, 32]. Only half of the
STIVEA patients will have been randomised to steroid
treatment as part of the trial.
2. moderate to large improvements in EQ-5D and SF-6D
(ES[0.5) in BRSBR patients. In a US study of
arthritis patients receiving inﬂiximab, an anti-TNFa
treatment, patients were shown to have moderate
(EQ-5D 0.6) to large (SF-6D 1.4) ES [11].
3. small (ES * 0.2) improvement or deterioration in
patients reporting changes in health over 12 months of
the BROSG trial. In a study using similar VAS deﬁned
and self-reported improvement and deterioration, ES
for deterioration ranged from -0.24 (EQ-5D) to -0.55
(SF-6D) and improvement ranged from 0.36 (EQ-5D)
to 0.54 (SF-6D) [10]. However, these estimates were
based on groups with no limit for deterioration or
improvement. Our deﬁnition of 20–50% improvement/
deterioration was restrictive; therefore, it is likely the
ES will be lower.
4. Small deterioration (ES * 0.2) in the BROSG and
BSRBR control groups. The progression and duration
of arthritis is associated with small gradual increases in
functional disability (approximately 0.033 per annum)
and accumulated joint destruction [31]. The reduction
in EQ-5D and SF-6D scores would be expected to
mirror the gradual increase in burden of disease.
Statistical analysis
We treated responsiveness as a part of the validation
process of an outcome measure which requires longitudinal
data and methods distinct from other techniques used
to assess other types of validity [33]. We deﬁned respon-
siveness using the effect size (ES) and standardised
response mean (SRM) [34]. Both provide a ratio of signal
(mean change) to noise (standard deviation). ES for this
study was calculated using a formula based on Cohen’s d,
d ¼  x1    x2=s ðÞ . The source of the standard deviation (s)i n
Cohen’s formula is not speciﬁed, as the true standard
deviation is assumed to remain the same regardless of the
mean of the population. The ES in this study used mean
change between baseline and a follow-up assessment
and the standard deviation of the group at baseline:
ES = l1 - l2/rv1, where l1 = mean at follow-up,
l2 = mean at baseline and rv1 = standard deviation of the
group mean at baseline. The SRM is calculated in the same
way as the ES, although the standard deviation (s) is the
standard deviation of the mean change  x1    x2 ðÞ instead of
the baseline standard deviation: SRM = l1 - l2/r(v1 -
v2), where l1 = mean at follow-up, l2 = mean at baseline,
and r(v1 - v2) = standard deviation of the group change
between baseline and follow-up.
The Pearson product-moment correlation was used to
calculate the correlation of change between measures. The
comparative strength of correlations between a disease-
speciﬁc outcome measure and the EQ-5D and SF-6D utility
measures was compared using Steiger’s Z test for two
correlated correlation coefﬁcients [35, 36].
Floor and ceiling effects (the percentage of patients
occupying the worst/best health states) were calculated and
considered small if B15% of patients occupy the worst and
best health states, respectively, and serious if [15% of
patients occupy these states. These criteria have been used
previously in reviews of outcome measures in musculo-
skeletal disease [8, 37].
Results
Baseline characteristics
The study population consisted of 466 patients from the
BROSG trial, 182 patients from STIVEA, 223 patients
from the BSRBR register and 188 from the BSRBR
comparison cohort. One hundred and eighty-eight (84%) of
the BSRBR patients received adalimumab and 35
(16%) received inﬂiximab. The disease duration of patients
ranged from 7.8 weeks (s.d. 2.6) in the STIVEA trial
to 13.4 years (s.d. 11.5) in the BSRBR. There were dif-
ferences in demographic and clinical characteristics
between the four groups of patients (Table 2).
Patients in the BROSG study had the highest mean EQ-
5D scores (mean 0.59, s.d. 0.22) followed by the BSRBR
control arm (mean 0.55, s.d. 0.27), STIVEA (mean 0.46,
s.d. 0.31) and the BSRBR group (mean 0.34, s.d. 0.33). The
pattern was the same for SF-6D scores, but these scores
were consistently higher than EQ-5D scores; mean scores
ranged from 0.64 (s.d. 0.13) in BROSG to 0.50 (s.d. 0.09)
in the BSRBR treatment arm.
1198 Qual Life Res (2009) 18:1195–1205
123Change over time
A EULAR response could be calculated for 161 BSRBR
patients (72%) and 171 STIVEA patients (94%). One
hundred and thirty-two (82%) of the BSRBR patients and
135 (79%) of the STIVEA patients were responders. Over
half of the STIVEA responders (55%) and two-thirds of
BSRBR (35%) were good responders.
A total of 436 out of 466 patients in the BROSG trial
attendeda12-monthfollow-upand completed the EQ-VAS.
Eighty-one patients (19%) had an EQ-VAS score worse
([20 &\50%) than baseline at the 1-year follow-up, and 62
patients (14%) had an EQ-VAS score better ([20 &\50%)
than at baseline. The improvers were called BROSG(I) and
the deterioraters BROSG(D). The proportion of patients
from each treatment arm of the BROSG trial was similar in
eachgroup.Fourhundredandsixpatientscompleted3 years
of follow-up in the BROSG trial.
Patients in the BROSG trial and BROSG(D) and the
BSRBR control arm deteriorated over the period of follow-
up; mean change in EQ-5D ranged from -0.05 to -0.13,
and SF-6D ranged from -0.01 to -0.04 (Table 3). Dete-
rioration in SF-6D in the BSRBR control arm was minimal
(mean -0.01, s.d. 0.09). The HAQ scores for all these
groups deteriorated (mean 0.09–0.16). The DAS28 scores
did not show consistent direction of change in these groups,
worsening only in the BROSG(D) reported group.
In BROSG(I) patients and those in the BSRBR and
STIVEA trial, the EQ-5D (mean 0.06–0.20) and SF-6D
(mean 0.03–0.13) indicated improvement. All other
outcome measures reﬂected this improvement over the
follow-up period apart from HAQ, which deteriorated in the
BROSG(I) patients (0.07). The improvement in patients in
the BSRBR and STIVEA studies was considerable for all
outcome measures.
ES and SRM
The hypothesised magnitude of change, based on the ES,
for each of the 6 groups of patients deﬁned by direction of
expected change, was equaled or exceeded on 5 occasions
by the EQ-5D, and on 4 occasions by the SF-6D (Table 4).
The ES for the EQ-5D in patients in the BSRBR group
(ES = 0.46) was slightly smaller than the hypothesised
moderate response (ES * 0.5). The ES for the SF-6D was
smaller than expected for patients in the BROSG group
(ES = 0.15) and the BSRBR Control (ES = 0.08) group
where a small effect size was expected (ES * 0.20); the
latter group had a very small effect size. The ES for
patients from patients reporting a deterioration over 1 year
of follow-up (BROSG(D) was larger than anticipated for
both the EQ-5D (ES = 0.62) and SF-6D (ES = 0.35). The
ES for improvement in patients from STIVEA (EQ-5D
ES = 0.64, SF-6D ES = 0.97) unexpectedly exceeded
those for BSRBR(EQ-5D ES = 0.46, SF-6D ES = 0.82).
Responsiveness, whether assessed by the ES or SRM,
yielded largely similar results (Table 4). However, the
comparative responsiveness of the EQ-5D and SF-6D dif-
fered according to the direction of change. When health
deteriorated over the follow-up period, the EQ-5D was
consistently more responsive than the SF-6D. The EQ-5D
was most notably more responsive than the SF-6D in the
Table 2 Baseline characteristics of patients from the four cohorts, ordered by mean utility score
BROSG
n = 466
BSRBR control
n = 188
STIVEA
n = 182
BSRBR
n = 223
Age (years) 60.6 (11.2) 60.2 (11.7) 55.5 (15.0) 57.9 (12.2)
Sex, female, n (%) 317 (68%) 142 (76%) 182 (69%) 168 (75%)
Disease duration (years) 12.5 (6.7) 11.8 (10.9) 0.15 (0.05) 13.4 (11.5)
EQ-5D 0.59 (0.22) 0.55 (0.27) 0.46 (0.31) 0.34 (0.33)
SF-6D 0.64 (0.13) 0.59 (0.12) 0.56 (0.13) 0.50 (0.09)
EQ-VAS 64.8 (18.1) 58.3 (18.7) 58.8 (21.3) 48.1 (21.1)
HAQ
a 1.28 (0.70) 1.38 (0.75) 1.23 (0.69) 1.92 (0.60)
DAS28
a 4.04 (1.26) 4.99 (1.09) 5.39 (1.10) 6.41 (1.03)
28 Tender joint count
a 5.1 (5.9) 7.6 (6.0) 10.6 (6.6) 15.3 (7.2)
28 Swollen joint count
a 4.2 (4.2) 5.0 (4.5) 8.9 (5.1) 10.3 (6.4)
ESR (mm/h)
a 23.8 (22.9) 35.1 (24.1) 36.6 (26.5) 42.7 (27.8)
Numbers are mean (s.d.) unless otherwise stated
EQ-5D EuroQol-5D, SF-6D short form-6D, EQ-VAS EuroQol visual analogue scale, STIVEA steroids in very early arthritis, BROSG British
Rheumatoid Outcome Study Group, BSRBR British Society for Rheumatology Biologics Register, HAQ Health Assessment Questionnaire,
DAS28 Disease Activity Score based on 28 swollen joint counts, ESR = erythrocyte sedimentation rate, s.d., standard deviation
a Higher values denote more severe disease
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respond to deterioration [mean change -0.01 (0.09)] in this
group. All ES ratios indicated that the EQ-5D was more
than 1.5 times more responsive to deterioration. In contrast,
when patients improved over follow-up, the SF-6D was
more responsive than the EQ-5D, particularly in the STI-
VEA (ES ratio 1.5) and BSRBR groups (ES ratio 1.8)
where a large improvement was detected.
Correlation
The correlation of change in EQ-5D and SF-6D ranged
from 0.25 in the BROSG 12-month deterioration group to
0.48 in the STIVEA patients (Table 5). The change in SF-
6D correlated more strongly than the change in EQ-5D
with change in patient EQ-VAS rated health in all of the
cohorts apart from the BSRBR control cohort group, where
correlations were equal. Change in DAS28 and its com-
ponents (tender and swollen joint counts, ESR) was gen-
erally more strongly correlated with change in SF-6D score
than change in EQ-5D score. Similarly, change in HAQ in
STIVEA and BSRBR was signiﬁcantly more strongly
correlated with the change in SF-6D score than change in
EQ-5D score. The SF-6D was signiﬁcantly more strongly
correlated than the EQ-5D with the DAS28 in the BROSG
12-month improvement group.
Table 3 Mean change over time (s.d.) in each of the groups of patients
BROSG
(n = 406)
BROSG (D)
(n = 81)
BROSG (I)
(n = 62)
BSRBR control
(n = 188)
BSRBR
(n = 223)
STIVEA
(n = 182)
Duration (months) 36 12 12 6 6 12
EQ-5D -0.05 (0.24) -0.13 (0.24) 0.06 (0.27) -0.07 (0.28) 0.15 (0.34) 0.20 (0.31)
SF-6D -0.02 (0.11) -0.04 (0.10) 0.03 (0.09) -0.01 (0.09) 0.08 (0.12) 0.13 (0.16)
EQ-VAS -11.8 (28.8) N/a N/a -1.08 (17.8) 10.9 (24.8) 11.2 (25.9)
HAQ
a 0.16 (0.47) 0.13 (0.48) 0.07 (0.33) 0.09 (0.92) -0.33 (0.61) -0.41 (0.68)
DAS28
a -0.09 (1.22) 0.53 (0.99) -0.03 (0.92) -0.87 (1.36) -2.23 (1.47) -1.85 (1.41)
28 Tender joint
count
a
-0.2 (5.6) 2.4 (5.7) -0.6 (6.9) – -9.6 (7.9) -6.0 (7.6)
28 Swollen joint
count
a
-1.3 (4.5) 1.3 (4.5) 0.2 (5.0) – -6.6 (6.2) -6.3 (5.4)
ESR (mm/hr)
a 1.0 (20.2) -0.4 (30.8) -2.2 (17.2) – -13.6 (22.4) -15.1 (27.5)
BROSG(D) = EQ-VAS score worse ([20 &\50%) than baseline; BROSG(I) = EQ-VAS score better ([20 &\50%) than at baseline
Follow-up periods differ due to the follow-up assessments available in each study
EQ-5D EuroQol-5D, SF-6D Short Form-6D, EQ-VAS EuroQol visual analogue scale, STIVEA steroids in very early arthritis, BROSG British
Rheumatoid Outcome Study Group, BSRBR British Society for Rheumatology Biologics Register, HAQ Health Assessment Questionnaire,
DAS28 Disease Activity Score based on 28 swollen joint counts, ESR erythrocyte sedimentation rate, s.d. standard deviation
a Higher values denote more severe disease
Table 4 Responsiveness of the EQ-5D and SF-6D to change in each of the groups, ordered by increasing magnitude of change (EQ-5D)
Mean (s.d.) change EQ-5D Effect size (ES) ES ratio
a Standardised response mean (SRM) SRM ratio
a
HD EQ-5D SF-6D EQ-5D SF-6D
Deterioration
BROSG -0.05 (0.24) *0.20 0.24 0.15 1.6 0.22 0.17 1.3
BSRBR control -0.07 (0.28) *0.20 0.24 0.08 3.0 0.23 0.08 2.9
BROSG(D) (1 year) -0.13 (0.24) *0.20 0.62 0.35 1.8 0.51 0.37 1.4
Improvement
BROSG(I) (1 year) 0.06 (0.27) *0.20 0.22 0.25 1.1 0.21 0.29 1.4
BSRBR 0.15 (0.34) [0.50 0.46 0.82 1.8 0.44 0.64 1.5
STIVEA 0.20 (0.31) *0.50 0.64 0.97 1.5 0.64 0.83 1.3
HD hypothesised change (effect size), BROSG (D) = EQ-VAS score worse ([20% &\50%) than baseline; BROSG (I) = EQ-VAS score better
([20% &\50%) than at baseline
EQ-5D EuroQol-5D, SF-6D Short Form-6D, STIVEA steroids in very early arthritis, BROSG British Rheumatoid Outcome Study Group, BSRBR
British Society for Rheumatology Biologics Register, s.d. standard deviation
a Calculated as the larger of the effect size for the EQ-5D or SF-6D divided by the smaller effect size
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Overall ﬂoor and ceiling effects of the EQ-5D and SF-6D
were small in this study (Table 6). No patient scored at the
ﬂoor of the EQ-5D, and 2% or fewer scored at the ﬂoor of
the SF-6D. However, ﬂoor effects existed for individual
domains. Floor effects for EQ-5D pain/discomfort were
small in the BROSG (7%) and BSRBR control groups
(9%), but serious (26% in STIVEA and 39% in BSRBR).
Serious ﬂoor effects were also evident in the role limitation
subscale of the SF-6D (32–65%), the vitality subscale (19–
36%) and in the physical functioning scale (18–24%) in the
BRSBR, BRSBR control and STIVEA groups.
There were no serious ceiling effects for the EQ-5D
(\1–8%) and no patient scored at the ceiling of the SF-6D.
However, serious ceiling effects existed in the self-care
(22–49%) and anxiety/depression (44–66%) EQ-5D
domains for all groups, in the usual activities domain for
STIVEA (15%), BROSG (22%) and the BSRBR control
(17%) groups, and mobility in BROSG (22%), BSRBR
control (23%) and STIVEA (36%). Ceiling effects were
serious in all groups for the social functioning subscale
(18–45%) and all groups but STIVEA (12%) for the mental
health subscale (16–27%). In addition, there were small to
serious (7–27%) ceiling effects in the mobility subscale.
Discussion
This study is the ﬁrst to compare the responsiveness of the
EQ-5D and SF-6D to longitudinal changes in UK RA
patients with different expected disease trajectories. These
ranged from patients with early disease expected to
improve through to patients with severe long-standing
disease expected to deteriorate. Our results have high-
lighted key differences in the ability of the EQ-5D and SF-
6D to measure change. Of note, the EQ-5D was more
responsive to deterioration in health than the SF-6D,
whereas the SF-6D was more responsive to improvement.
The SF-6D was unable to detect further deterioration in a
group of patients with already severe disease.
The ﬁnding that the EQ-5D is more responsive to
deterioration than the SF-6D is in keeping with all previous
reports in the literature [10, 12]. Similarly, the greater
responsiveness of the SF-6D to improvement supports the
majority of previous ﬁndings [10, 11]. All previous studies
have suggested that both measures are generally responsive
to change in the RA patient [8]. However, the SF-6D has a
clear limitation in severe RA patients, which has not pre-
viously been demonstrated.
The ability of the SF-6D to detect change is thought to
be inhibited by the high ﬂoor of the measure. However, in
this study, few patients scored at the ﬂoor of the SF-6D in
any of the cohorts, although within-domain ﬂoor effects
were considerable for the role limitation, vitality and
physical functioning domains. These domains relate to key
aspects of the limitation caused by RA, and the ﬂoor effects
may explain the lack of response when patients deterio-
rated further in the BSRBR cohort. These ﬂoor effects were
severe but smaller in the groups where the SF-6D was
responsive to deterioration. However, the correlations of
change in the SF-6D with change in the HAQ and DAS28
scores were stronger than corresponding correlations with
the EQ-5D. This suggests that the superior responsiveness
Table 5 Correlation of change between outcome measures
EQ-5D SF-6D DAS28 HAQ EQ-VAS 28 Tender 28 Swollen ESR
STIVEA EQ-5D – 0.48 -0.40 -0.53 -0.52 -0.27 -0.04 -0.35
SF-6D 0.48 – -0.50 -0.67
  -0.59 -0.34 -0.16 -0.31
BROSG (3-year) EQ-5D – 0.38 -0.16 -0.28 0.26 -0.11 0.08 -0.18
SF-6D 0.38 – -0.17 -0.36 0.32 -0.10 0.01 -0.23
BROSG(D) (1 year) EQ-5D – 0.25 -0.16 -0.14 0.16 -0.03 -0.13 -0.11
SF-6D 0.25 – -0.29 -0.24 0.31 -0.04 -0.11 -0.12
BROSG(I) (1 year) EQ-5D – 0.37 -0.17 -0.31 0.19 -0.16 -0.03 0.01
SF-6D 0.37 – -0.37
  -0.20 0.32 -0.18 -0.25
  -0.16
BSRBR EQ-5D – 0.44 -0.16 -0.37 0.41 -0.14 -0.07 0.01
SF-6D 0.44 – -0.34 -0.64
   0.48 -0.28 -0.23
  0.04
BSRBR control EQ-5D – 0.38 -0.16 -0.22 0.26 – – –
SF-6D 0.38 – -0.23 -0.21 0.26 – – –
BROSG(D) = EQ-VAS score worse ([20 &\50%) than baseline; BROSG(I) = EQ-VAS score better ([20 &\50%) than at baseline
EQ-5D EuroQol-5D, SF-6D Short Form-6D, EQ-VAS EuroQol Visual Analogue Scale, STIVEA steroids in very early arthritis, BROSG British
Rheumatoid Outcome Study Group, BSRBR British Society for Rheumatology Biologics Register, HAQ Health Assessment Questionnaire,
DAS28 Disease Activity Score based on 28 swollen joint counts, ESR erythrocyte sedimentation rate, s.d. standard deviation
Steiger’s Z-test:
  P\0.05;
   P\0.01
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123of the EQ-5D to deterioration in health in this group is
related to some aspect other than functional disability or
disease activity. The EQ-5D had no ﬂoor effects in the
overall utility score or any domains in the BSRBR control
group, providing scope for detecting extra deterioration in
all aspects of disease measured by this instrument in these
patients. The domains of the SF-6D with ﬂoor effects, role
limitation, physical functioning and vitality are likely to be
captured by the self-care and usual activities domains of
the EQ-5D, which have no ﬂoor effects.
The mean change of the EQ-5D exceeded the mean
change of the SF-6D in all of the cohorts used in this study.
This has implications in the use of responsiveness statistics
and in using the measure for cost-effectiveness analyses.
The EQ-5D was less responsive than the SF-6D to
improvement despite the larger mean change using the
EQ-5D highlighting the variance around the measure. The
SF-6D has smaller increments between scoring levels than
the EQ-5D which allows patients to report smaller
improvements. This may explain why the SF-6D is more
responsive to small but important improvements. The
SF-6D shows relatively small absolute change but has a
small standard deviation [11, 12], which leads to a good
responsiveness statistics. Changes in a single domain of the
EQ-5D can result in changes of 0.036–0.655 in the overall
utility score. Therefore, change in a small number of
patients can lead to a large group mean change effect. The
impact on the overall EQ-5D scores is largest when a
domain is scored at the most severe level for the ﬁrst time.
This attracts both reductions in utility associated with the
change in domain (range 0.094–0.386) and reduction of
0.269 for the ﬁrst domain scored as severe, known as the
N3 term.
The larger mean change in improving and deteriorating
patients suggests that an intervention will be more likely to
be seen as cost-effective if assessed using the EQ-5D rather
than the SF-6D. In cost-effectiveness analysis, the incre-
mental cost of an intervention is divided by its incremental
effectiveness, measured using a measure such as the
EQ-5D or SF-6D. The larger the effect estimate, the lower
the cost per unit of effect. A recent study in RA reported
that change estimated using the EQ-5D resulted in a cost
per QALY over 50% lower than the cost per QALY cal-
culated using the SF-6D [38]. However, as the mean effect
is only an estimate, the uncertainty around the estimate
must be presented. The smaller variance of the SF-6D
should result in less uncertainty in a concerning the relative
cost-effectiveness of two treatments.
There are weaknesses in the use of responsiveness sta-
tistics. There is an array of such statistics, and different
methods may lead to different conclusions [33, 39, 40]. To
date,nomeasurehasbeenprovenconclusivelytobesuperior
to another. Furthermore, responsiveness statistics is limited
in the information they convey. They give an indication of
whether a measure can detect a statistically signiﬁcant
difference between two groups. However, statistical signif-
icance is dependent on factors external to the measure under
study such as sample size and does not indicate whether the
changedetectedismeaningfuloruseful[33,41].TheESand
SRM express change in terms of the standard deviation and
provide a useful indication of the relative sample sizes
requiredtodetectstatisticallysigniﬁcant differencebetween
Table 6 Floor/ceiling effects for the EQ-5D and SF-6D
BROSG (%) BROSG (D) (%) BROSG (I) (%) BSRBR control (%) STIVEA (%) BSRBR (%)
n = 406 n = 81 n = 62 n = 188 n = 182 n = 223
EQ-5D 0/1 0/\1 0/8 0/6 0/\1 0/1
Mobility 0/22 0/10 0/25 0/23 0/36 0/10
Self-care \1/47 \1/32 0/49 2/43 1/42 2/22
Usual activities 4/22 9/8 2/23 4/17 14/15 15/4
Pain/discomfort 8/7 15/2 2/6 13/9 26/1 39/3
Anxiety/depression 1/66 3/62 0/65 3/56 4/54 5/44
SF-6D 2/0 \1/0 0/0 2/0 2/0 2/0
Physical functioning [6] 12/1 18/2 12/1 18/2 18/1 24/1
Role limitation [4] 39/24 52/15 32/27 64/7 48/14 65/7
Social functioning [5] 4/39 8/22 1/45 8/25 9/27 9/18
Pain [6] 2/2 3/3 0/2 8/2 22/1 11/2
Mental health [5] 3/22 7/16 2/25 5/28 6/12 3/27
Vital [5] 19/1 28/1 11/2 36/2 30/4 36/3
BROSG(D) = EQ-VAS score worse ([20 &\50%) than baseline; BROSG(I) = EQ-VAS score better ([20% &\50%) than at baseline
Numbers in brackets for SF-6D are the number of levels within domains
EQ-5D EuroQol-5D, SF-6D Short Form-6D, STIVEA steroids in very early arthritis, BROSG British Rheumatoid Outcome Study Group, BSRBR
British Society for Rheumatology Biologics Register
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123groups[39].ThebasisofESandSRMisthatrelevantchange
should exceed random noise or the variability in unchanged
patients. These measures used without an anchor of impor-
tant change give no information about the ability of the
instrument to measure change in the underlying construct,
[33] and essentially are measures of sensitivity. We used the
responsiveness measures alongside some external reference
of change, for example the change in EQ-VAS score, or
response to treatment. This was not possible for the overall
BROSG data or for the BSRBR control cohort, and we,
therefore, cannot assume that all patients in these cohorts
deteriorated; the HAQ score for these cohorts suggested
deterioration of functional disability approaching the mini-
mally important difference for clinical practice [42]; how-
ever, the DAS28 scores in the BSRBR control cohort
suggested some improvement in disease activity from the
high baseline level.
Comparison of change in different cohorts was limited by
the different follow-up periods used. The analysis relied on
data collected concurrently within each study and was
therefore limited by the designof each cohort. Patientsin the
BSRBRtreatmentandcontrolstudieswereonlyfollowedfor
6 months. This may be sufﬁcient to capture the large
expected improvements in patients treated with anti-TNF
therapy, but may be insufﬁcient to capture clinically mean-
ingful deterioration in patients in the control arm continuing
withtraditionaltreatmentofRA.However,thechangeinEQ-
5D for this latter group of patients was in excess of estimates
of the minimum important difference for this measure [8].
A further limitation of the ES is that in highly selected
groups of patients, the ES may be artiﬁcially inﬂated. The
BROSG and STIVEA trials by deﬁnition were selected
groupsofpatients.ItwasthereforeimportanttousetheSRM
to verify the results based on the ES. In only one instance
were the conclusions based on the ES and SRM conﬂicting,
and where this occurred, the difference between respon-
siveness ofthe EQ-5D andSF-6D wasmarginal.Finally, the
methods of the ES and SRM assume that all patients change
in the same direction [39]. It is likely that there is some
misclassiﬁcationofchangebetweentheanchorsandsomeof
the outcome measures. This may be particularly true for the
EQ-VAS scale which frames a patient’s health on the day in
question; therefore, change in EQ-VAS assesses the differ-
ence between a person’s health on 2 days, 1 year apart. The
framing of the question gives considerable potential for
transientandpossiblytrivialfactorstoinﬂuencetheratingof
change in health. However, the design of this study aimed to
classify patients on the basis of important change and only
compared responsiveness of the EQ-5D and SF-6D in
patients changing in the same direction by more than a
certain amount.
The ability to measure change in the RA patient is
indicative of longitudinal construct validity [43]. Concerns
have been voiced about the ability of the EQ-5D to mea-
sure change due to its bimodal distribution, crude scoring
and possible ceiling effects within domains [11, 12, 44,
45]. These issues were evident in the data used in this
study, but the EQ-5D appeared to respond to both
improvement and deterioration. The EQ-5D was more
responsive to deterioration, and the SF-6D more responsive
to improvement in patients with inﬂammatory arthritis. The
SF-6D does not appear appropriate for use in patients with
established severe RA, who are expected to experience
disease progression. Responsiveness of a measure affects
the power of a given sample size to detect a statistically
signiﬁcant difference. As an outcome measure in an epi-
demiological setting, the SF-6D requires a smaller sample
size than the EQ-5D to detect improvement in patients
whose health is getting better. The opposite is true in
worsening patients. In economic analysis, however, the
approach is different. The incremental cost-effectiveness
ratio (ICER) is the primary estimate of cost-effectiveness
of an intervention, and if this value is less than a decision-
makers willingness to pay, then the intervention should be
adopted [46, 47]. The EQ-5D consistently provided larger
mean change estimates than the SF-6D, even when less
responsive than the SF-6D (due to the greater variance
around the EQ-5D), which would result in a more
optimistic incremental cost-effectiveness ratio.
Conclusion
The results from the four cohorts of patients used in this
study demonstrate that the comparative responsiveness of
the EQ-5D and SF-6D differs according to the direction of
change; the EQ-5D was more responsive to deterioration in
health than the SF-6D, whereas the SF-6D was more
responsivetoimprovement. Thelevel ofmean change ofthe
EQ-5D, which is consistently larger than that of the SF-6D,
has potentially serious implications for decision-making on
the basis of cost-effectiveness analysis; the EQ-5D is likely
to provide more optimistic cost-effectiveness ratios than the
SF-6D.Our results support the responsiveness of the EQ-5D
to improvement and deterioration across a range of arthritis
states/severity. The SF-6D was responsive to improvement
in cohorts of patients with range of arthritis severity and to
deterioration in patients with established stable disease;
however, use of the SF-6D in patients with severe progres-
sive disease may be inappropriate.
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